Andere Sprachen Alkermes plc

Aktien

A1JKVH

IE00B56GVS15

ALKS

Markt geschlossen - Nasdaq Andere Börsenplätze 21:59:47 04.06.2024			% 5 Tage	% 1. Jan.
23,66 ^USD	-1,66 %		-0,40 %	-14,73 %

24.05.	ALKERMES PLC : Cantor Fitzgerald bekräftigt seine Kaufempfehlung	ZM
02.05.	ALKERMES PLC : UBS behält Verkaufen-Bewertung bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alkermes to Participate in Two Upcoming Investor Conferences	29.05.
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024	28.05.
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk	02.05.
Alkermes : Q1 2024 Earnings Call Script FINAL 5 1 2024	02.05.
Alkermes : ALKS Q1 2024 Earnings Slides FINAL 5 1 2024	02.05.
Alkermes's Q1 Earnings, Revenue Grow But Miss Street View	01.05.
Alkermes: Q1 Earnings Snapshot	01.05.
Earnings Flash (ALKS) ALKERMES Reports Q1 Revenue $350.4M, vs. Street Est of $360.3M	01.05.
Earnings Flash (ALKS) ALKERMES Posts Q1 EPS $0.43, vs. Street Est of $0.58	01.05.
Alkermes plc Reiterates Earnings Guidance for the Year 2024	01.05.
Alkermes plc Reports Earnings Results for the First Quarter Ended March 31, 2024	01.05.
Alkermes plc Reports First Quarter 2024 Financial Results	01.05.
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1	24.04.
Alkermes to Report First Quarter Financial Results on May 1, 2024	17.04.
Alkermes Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	10.04.
BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024	09.04.
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	09.04.
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study	09.04.
Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	09.04.
Alkermes Insider Sold Shares Worth $292,740, According to a Recent SEC Filing	19.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alkermes plc

Aktien

A1JKVH

IE00B56GVS15

ALKS

Andere Sprachen

Filter